Consensus Checkpoint Therapeutics, Inc.

Equities

CKPT

US1628282063

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
1.88 ^USD	+5.62%		+25.33%	-17.90%

May. 10	Checkpoint Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 22	Checkpoint Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Evolution of the average Target Price on Checkpoint Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

e2fdf145ec7c8e50bad1f45bc518.m60WQG0PiMGtLorgiQ3jjvTZLj0paUKjevJDv9ETKJ0.05g7FjxY4rfFZOfVujmavpW_G0gcLDjxFbYR_o5kXdyuzmINA0HgqcFDzw~76e8f723e219ce8fd0301107070ae071

Analyst Recommendations on Checkpoint Therapeutics, Inc.

B. Riley Lowers Checkpoint Therapeutics' Price Target to $4 From $8, Keeps Buy Rating	Dec. 20	MT
North American Morning Briefing : Stocks Futures Steady on Rates Optimism	Nov. 20	DJ
B. Riley Lowers Checkpoint Therapeutics' Price Target to $8 From $15, Keeps Buy Rating	23-08-22	MT
Lake Street Adjusts Checkpoint Therapeutics Price Target to $14 From $16, Maintains Buy Rating	23-08-15	MT
Ladenburg Thalmann Adjusts Checkpoint Therapeutics' Price Target to $47 From $65, Keeps Buy Rating	23-08-15	MT
Cantor Fitzgerald Adjusts Checkpoint Therapeutics' Price Target to $14 From $19, Keeps Overweight Rating	23-08-15	MT
Lake Street Adjusts Checkpoint Therapeutics' Price Target to $16 From $22, Keeps Buy Rating	23-05-30	MT
Ladenburg Thalmann Lowers Price Target on Checkpoint Therapeutics to $65 From $69, Maintains Buy Rating	23-05-17	MT
Cantor Fitzgerald Cuts Price Target on Checkpoint Therapeutics to $19 From $54, Maintains Overweight Rating	23-05-16	MT
HC Wainwright Adjusts Price Target on Checkpoint Therapeutics to $34 From $76, Maintains Buy Rating	23-04-28	MT
Lake Street Adjusts Price Target on Checkpoint Therapeutics to $22 From $32, Maintains Buy Rating	23-04-04	MT
Ladenburg Thalmann Adjusts Checkpoint Therapeutics Price Target to $69 From $96, Maintains Buy Rating	23-04-03	MT
Lake Street Adjusts Price Target on Checkpoint Therapeutics to $41 From $70, Maintains Buy Rating	23-01-05	MT
HC Wainwright Adjusts Checkpoint Therapeutics' Price Target to $76 From $26, Keeps Buy Rating	22-12-23	MT
B. Riley Raises Checkpoint Therapeutics' Price Target to $15 From $7 Following Reverse Split, Equity Offering; Keeps Buy Rating	22-12-19	MT
B. Riley Resumes Checkpoint Therapeutics at Buy with $7 PT, Notes Focus on Cutaneous Squamous Cell Carcinoma Regulatory Approval Process Initiating by Year End 2022	22-07-14	MT
CORRECTION : Wedbush Adds Check Point Software Technologies to Best Ideas List, Maintains Outperform Rating, $145 Price Target	22-07-12	MT
Wedbush Raises Price Target for Checkpoint Therapeutics to $76 From $68, Maintains Outperform Rating, Adds to Best Ideas List	22-07-12	MT
HC Wainwright Adjusts Checkpoint Therapeutics' Price Target to $26 From $17, Maintains Buy Rating	22-01-25	MT
CHECKPOINT THERAPEUTICS : B. Riley Starts Checkpoint Therapeutics at Buy with $18 PT, Believes Potential of Lead Asset Cosibelimab Not Fully Appreciated	21-06-09	MT
CHECKPOINT THERAPEUTICS : Cantor Fitzgerald Starts Checkpoint Therapeutics at Overweight With $16 Price Target	21-01-20	MT
Avenue Therapeutics : Biotech incubator taps investors through in-house brokerage	18-08-02	RE